GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Return-on-Tangible-Equity

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Prestige Consumer Healthcare's annualized net income for the quarter that ended in Dec. 2023 was $212 Mil. Prestige Consumer Healthcare's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-1,287 Mil. Therefore, Prestige Consumer Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was Negative Tangible Equity%.

The historical rank and industry rank for Prestige Consumer Healthcare's Return-on-Tangible-Equity or its related term are showing as below:

PBH's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.73
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Prestige Consumer Healthcare Return-on-Tangible-Equity Historical Data

The historical data trend for Prestige Consumer Healthcare's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare Return-on-Tangible-Equity Chart

Prestige Consumer Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity -

Prestige Consumer Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity - Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Prestige Consumer Healthcare's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Return-on-Tangible-Equity falls into.



Prestige Consumer Healthcare Return-on-Tangible-Equity Calculation

Prestige Consumer Healthcare's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-82.306/( (-1698+-1422.362 )/ 2 )
=-82.306/-1560.181
=N/A %

Prestige Consumer Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=212.184/( (-1319.151+-1255.83)/ 2 )
=212.184/-1287.4905
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Prestige Consumer Healthcare  (NYSE:PBH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Prestige Consumer Healthcare Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591